The Food and Drug Administration granted marketing approval to Lannett Co. Inc. for its generic version of Phentermine hydrochloride, a weight-reduction medicine marketed by Sandoz. (Source: bizjournals.com Health Care:Health Insurance headlines)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
The Food and Drug Administration granted marketing approval to Lannett Co. Inc. for its generic version of Phentermine hydrochloride, a weight-reduction medicine marketed by Sandoz. (Source: bizjournals.com Health Care:Biotechnology headlines)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic BP reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Clinical Endocrinology News)
SAN DIEGO (MedPage Today) — A combination of phentermine and topiramate (Qnexa) appears to induce weight loss and a decrease in metabolic risk parameters for cardiovascular disease in obese patients, researchers reported here. (Source: MedPage Today Endocrinology)
MedWorm Message: Register for MedMatcha, MedWorm’s m edical advertising network, and receive $5 free advertising.
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Family Practice News)
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Cardiology News)
The highest dose of an investigational weight-loss therapy, a combination of very low-dose phentermine and controlled-release topiramate, reduces body weight by around 10% after a year of treatment…
For complete story visit theheart.org. (Source: theHeart.org)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free adver tising.
So urce: BioSpace
Area: News
VIVUS Inc. has announced positive results from two phase III 56-week studies (EQUIP and CONQUER) of its investigational weight loss treatment QnexaT, a once daily oral, controlled-release formulation of low dose phentermine and topiramate.
The phase III programme evaluated three doses of Qnexa (milligrams phentermine and controlled re lease topiramate, respectively): Qnexa 15/92 (full dose), Qnexa 7.5/46 (more…)
Phentermine may help kick-start your weight loss, but it’s not a permanent solution.Sponsored by:Chemotherapy.com – http://www.chemotherapy.com (Source: MayoClinic.com Full Feed)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Phentermine — Combine phentermine with diet and exercise to boost weight loss.
Sponsored by:Chemotherapy.com – http://www.chemotherapy.com (Source: MayoClinic.com – Ask a Specialist)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.